Lymphoma Clinical Trials

Lymphoma clinical trials provide ways for patients to access some of the newest and most innovative therapies before those therapies are made available at other hospitals and cancer centers. Clinical trials are typically conducted to compare a new treatment option to the existing “best standard” of care, which can help researchers determine if the new therapy has the potential to be more effective (or cause fewer side effects) than other options that are currently being used. The results of these important trials can help researchers improve treatment options, survival rates and quality of life for current and future lymphoma patients.

Moffitt Cancer Center’s clinical trial program is one of the most robust in the region, conducting numerous studies that focus on both Hodgkin and non-Hodgkin lymphoma. Our lymphoma clinical trials give patients opportunities to access:

  • Novel chemotherapy drugs and combinations
  • Highly targeted radiation therapy delivery techniques
  • Innovative antibiotic and vaccination therapies
  • Treatment options for recurrent lymphomas
  • Treatment options for each specific lymphoma subtype

Moffitt’s lymphoma clinical trials are conducted by experienced researchers and oncologists. Each patient’s progress is continually monitored to ensure that he or she is responding optimally to the recommended treatment. Furthermore, participants are carefully screened for each trial based on individualized factors such as cancer type and age; this increases the likelihood that a patient will benefit more from the specific treatment being tested than the other options that are currently available. And, adaptations can be made to a patient’s treatment plan at any time.

Because of our dedication to conducting groundbreaking research and advancing lymphoma treatment, we have been named a Comprehensive Cancer Center by the National Cancer Institute. We are the only cancer center based in Florida to have received this prestigious recognition.

For more information about Moffitt Cancer Center’s lymphoma clinical trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form. We can determine if any of our ongoing studies are appropriate for you. No referral is needed to reach out to Moffitt Cancer Center.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 19627

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19715

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 19829

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20131

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

Disease Site: Other hematologic, Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20385

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin(Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Disease Site: Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20578

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20608

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20737

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release

Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20751

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21094

An Open Label, Multi-Cohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination with Chemotherapy in Patients with Advanced T-cell Lymphoma

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21096

A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy

Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 21122

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 90001

A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

Disease Site: Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20067

INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors after Hematopoietic Cell Transplantation

Disease Site: Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Hematopoietic

View Trial Details

CLINICAL TRIAL 20397

A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

View Trial Details

CLINICAL TRIAL 20372

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Disease Site: Non-Hodgkin's Lymphoma

View Trial Details